NCCN guideline:esophgeal cancer.

Obermannová R, Alsina M, Cervantes A, Leong T, Lordick F, Nilsson M, et al. Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33:992–1004.

Article  PubMed  Google Scholar 

Ando N, Kato H, Igaki H, Shinoda M, Ozawa S, Shimizu H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-Fluorouracil Versus Preoperative Chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 2012;19:68–74.

Article  PubMed  Google Scholar 

Van Hagen P, Hulshof MCCM, Van Lanschot JJB, Steyerberg EW, Henegouwen MIVB, Wijnhoven BPL, et al. Preoperative chemoradiotherapy for esophageal or junctional Cancer. N Engl J Med. 2012;366:2074–84.

Article  PubMed  Google Scholar 

Yang H, Liu H, Chen Y, Zhu C, Fang W, Yu Z, et al. Long-term efficacy of Neoadjuvant Chemoradiotherapy Plus surgery for the treatment of locally advanced esophageal squamous cell carcinoma. JAMA Surg. 2021;156:721–9.

Article  PubMed  PubMed Central  Google Scholar 

Kato K, Ito Y, Daiko H, Ozawa S, Ogata T, Hara H, et al. A randomized controlled phase III trial comparing two chemotherapy regimen and chemoradiotherapy regimen as neoadjuvant treatment for locally advanced esophageal cancer, JCOG1109 NExT study. JCO. 2022;40:238–238.

Article  Google Scholar 

Yokota T, Yasuda T, Kato H, Nozaki I, Sato H, Miyata Y, et al. Concordance of clinical diagnosis of T classification among physicians for locally advanced unresectable thoracic esophageal cancer. Int J Clin Oncol. 2018;23:73–80.

Article  PubMed  Google Scholar 

Hirohata R, Hamai Y, Hihara J, Emi M, Kurokawa T, Yoshikawa T, et al. Evaluation of Neoadjuvant Chemoradiotherapy followed by surgery for Borderline Resectable esophageal squamous cell carcinoma. World J Surg. 2022;46:1934–43.

Article  PubMed  Google Scholar 

Wang Z, Hu M, Hu Y, Li Q, Wu J, Fong WP, et al. Paclitaxel plus cisplatin and 5-fluorouracil induction chemotherapy for locally advanced borderline-resectable esophageal squamous cell carcinoma: a phase II clinical trial. Esophagus. 2022;19:120–8.

Article  PubMed  Google Scholar 

Suzuki T, Okamura A, Watanabe M, Mine S, Imamura Y, Asari T, et al. Neoadjuvant Chemoradiotherapy with Cisplatin Plus Fluorouracil for Borderline Resectable esophageal squamous cell carcinoma. Ann Surg Oncol. 2020;27:1510–7.

Article  PubMed  Google Scholar 

Nakajima M, Muroi H, Kikuchi M, Kubo T, Inoue N, Ihara K, et al. Therapeutic strategy aiming at R0 resection for borderline-resectable esophageal squamous cell carcinoma using induction chemotherapy with docetaxel, cisplatin, and 5-fluorouracil. Gen Thorac Cardiovasc Surg. 2023;71:584–90.

Article  PubMed  Google Scholar 

Lu Z, Wang J, Shu Y, Liu L, Kong L, Yang L, et al. Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial. BMJ. 2022;377:e068714.

Article  PubMed  PubMed Central  Google Scholar 

Sun J-M, Shen L, Shah MA, Enzinger P, Adenis A, Doi T, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet. 2021;398:759–71.

Article  CAS  PubMed  Google Scholar 

Doki Y, Ajani JA, Kato K, Xu J, Wyrwicz L, Motoyama S, et al. Nivolumab Combination Therapy in Advanced Esophageal squamous-cell carcinoma. N Engl J Med. 2022;386:449–62.

Article  CAS  PubMed  Google Scholar 

Luo H, Lu J, Bai Y, Mao T, Wang J, Fan Q, et al. Effect of Camrelizumab vs Placebo added to Chemotherapy on Survival and Progression-Free Survival in patients with Advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st Randomized Clinical Trial. JAMA. 2021;326:916–25.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Three-year follow-up of ATTRACTION-3. A phase III study of nivolumab (Nivo) in patients with advanced esophageal squamous cell carcinoma (ESCC) that is refractory or intolerant to previous chemotherapy. | Journal of Clinical Oncology [Internet]. [cited 2024 Jan 8]. https://doi.org/10.1200/JCO.2021.39.3_suppl.204

Shah MA, Kojima T, Hochhauser D, Enzinger P, Raimbourg J, Hollebecque A, et al. Efficacy and safety of Pembrolizumab for heavily pretreated patients with Advanced, metastatic adenocarcinoma or squamous cell carcinoma of the Esophagus: the phase 2 KEYNOTE-180 study. JAMA Oncol. 2019;5:546–50.

Article  PubMed  Google Scholar 

Zhang Z, Ye J, Li H, Gu D, Du M, Ai D, et al. Neoadjuvant sintilimab and chemotherapy in patients with resectable esophageal squamous cell carcinoma: a prospective, single-arm, phase 2 trial. Front Immunol. 2022;13:1031171.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang W, Xing X, Yeung S-CJ, Wang S, Chen W, Bao Y, et al. Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinoma. J Immunother Cancer. 2022;10:e003497.

Article  PubMed  PubMed Central  Google Scholar 

Yan X, Duan H, Ni Y, Zhou Y, Wang X, Qi H, et al. Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer: a prospective, single-arm, phase II study (TD-NICE). Int J Surg. 2022;103:106680.

Article  PubMed  Google Scholar 

Xing W, Zhao L, Zheng Y, Liu B, Liu X, Li T et al. The Sequence of Chemotherapy and Toripalimab Might Influence the Efficacy of Neoadjuvant Chemoimmunotherapy in Locally Advanced Esophageal Squamous Cell Cancer—A Phase II Study. Frontiers in Immunology [Internet]. 2021 [cited 2023 Dec 8];12. https://www.frontiersin.org/articles/https://doi.org/10.3389/fimmu.2021.772450

Picus D, Balfe DM, Koehler RE, Roper CL, Owen JW. Computed tomography in the staging of esophageal carcinoma. Radiology. 1983;146:433–8.

Article  CAS  PubMed  Google Scholar 

Thompson WM, Halvorsen RA, Foster WL, Williford ME, Postlethwait RW, Korobkin M. Computed tomography for staging esophageal and gastroesophageal cancer: reevaluation. AJR Am J Roentgenol. 1983;141:951–8.

Article  CAS  PubMed  Google Scholar 

Common Terminology Criteria for Adverse Events (CTCAE). | Protocol Development | CTEP [Internet]. [cited 2024 Jan 9]. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_50

Chinese National Cancer Center, Chinese Association of Thoracic Surgeons. Chinese Society for thoracic and Cardiovascular surgery, Chinese Society for diseases of the Esophagus. [Chinese guidelines on Perioperative Management of Resectable Esophageal Cancer (2023 edition)]. Zhonghua Yi Xue Za Zhi. 2023;103:2552–70.

Google Scholar 

Ajani JA, Barthel JS, Bentrem DJ, D’Amico TA, Das P, Denlinger CS, et al. Esophageal and Esophagogastric Junction cancers. J Natl Compr Canc Netw. 2011;9:830–87.

Article  PubMed  Google Scholar 

Han D, Li B, Zhao Q, Sun H, Dong J, Hao S, et al. The key clinical questions of Neoadjuvant Chemoradiotherapy for Resectable Esophageal Cancer—A Review. Front Oncol. 2022;12:890688.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yokota T, Hatooka S, Ura T, Abe T, Takahari D, Shitara K, et al. Docetaxel plus 5-Fluorouracil and cisplatin (DCF) induction chemotherapy for locally Advanced Borderline-resectable T4 esophageal Cancer. Anticancer Res. 2011;31:3535–41.

CAS  PubMed  Google Scholar 

Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27:450–61.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nagata Y, Yamamoto S, Kato K. Immune checkpoint inhibitors in esophageal cancer: clinical development and perspectives. Hum Vaccines Immunotherapeutics. 2022;18:2143177.

Article  Google Scholar 

Fan M, Dai L, Yan W, Yang Y, Lin Y, Chen K. Efficacy of programmed cell death protein 1 inhibitor in resection transformation treatment of esophageal cancer. Thorac Cancer. 2021;12:2182–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chao L, Liu J, Chen Y, Fan Y, Guo S, Zhang S. Benefits of camrelizumab plus carboplatin and albumin paclitaxel as induction therapy for locally advanced borderline resectable or unresectable esophageal squamous cell carcinoma. Thorac Cancer. 2024;15:622-9

Yin G-Q, Li Z-L, Li D. The Safety and Efficacy of Neoadjuvant Camrelizumab Plus Chemotherapy in patients with locally advanced esophageal squamous cell carcinoma: a retrospective study. Cancer Manag Res. 2022;14:2133–41.

Article  PubMed  PubMed Central  Google Scholar 

Wu Z, Zheng Q, Chen H, Xiang J, Hu H, Li H, et al. Efficacy and safety of neoadjuvant chemotherapy and immunotherapy in locally resectable advanced esophageal squamous cell carcinoma. J Thorac Dis. 2021;13:3518–28.

Article  PubMed  PubMed Central  Google Scholar 

Liu J, Yang Y, Liu Z, Fu X, Cai X, Li H et al. Original research: Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma. Journal for Immunotherapy of Cancer [Internet]. 2022 [cited 2024 Jan 5];10. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8961177/

Chen X, Xu X, Wang D, Liu J, Sun J, Lu M, et al. Neoadjuvant sintilimab and chemotherapy in patients with potentially resectable esophageal squamous cell carcinoma (KEEP-G 03): an open-label, single-arm, phase 2 trial. J Immunother Cancer. 2023;11:e005830.

Article